

Annual Review of Bladder Control Medications - Calendar Year 2011

Oklahoma HealthCare Authority

April 2012

Current Prior Authorization Criteria

Tier 2 Authorization Criteria:

1. Trial of one Tier 1 medication that yielded inadequate clinical response or adverse effects, or
2. A unique indication which the Tier 1 drugs lack.

Tier 3 Authorization Criteria:

1. Trial of all Tier 2 medications that yielded inadequate clinical response or adverse effects, or
2. A unique indication which the Tier 2 drugs lack.

This category will be grandfathered.


Bladder Control Medications		
Tier-1	Tier-2	Tier-3
Flavoxate (Urispas ®) Oxybutynin (Ditropan ®) Tolterodine (Detrol ®)	Oxybutynin ER Tabs (Ditropan XL ®)	Oxybutynin Patch (Oxytrol ®) Oxybutynin Gel (Gelnique ™) Tolterodine ER Tabs (Detrol LA ®) Fesoterodine (Toviaz ™) Solifenacin (VESIcare ®) Darifenacin (Enablex ®) Trospium (Sanctura ™) Trospium ER (Sanctura XR ™)

Utilization of Bladder Control Medications


Comparison of Calendar Years

Calendar Year	Members	Claims	Cost	Cost/Claim	Perdiem	Units	Days
2010	3,067	11,869	\$935,196.63	\$78.79	\$2.46	852,952	380,818
2011	2,936	11,984	\$933,126.68	\$77.86	\$2.47	902,234	378,360
% Change	-4.30%	1.00%	-0.20%	-1.20%	0.40%	5.80%	-0.60%
Change	-131	115	-\$2,069.95	-\$0.93	\$0.01	49,282	-2,458

Demographics of Members Utilizing Bladder Control Medications: CY 2011




Prescribers of Bladder Control Medications by Number of Claims: CY 2011



Prior Authorization of Bladder Control Medications

There were a total of 755 petitions submitted for this PBPA category during calendar year 2011. The following chart shows the status of the submitted petitions.

Status of Petitions for Bladder Control Medications: CY 2011



Market News and Updates

Upcoming Patent Expirations :

- **Enablex® (darifenacin)**- August 2016

Label Changes :

- **Detrol® (tolterodine) and Detrol LA® (tolterodine LA)**
 - September 2011- Warning adding of the potential to cause anaphylaxis and angioedema requiring hospitalization and emergency treatment with the first or subsequent doses.
- **Toviaz™ (fesoterodine)**
 - February 2011- Warning added that angioedema of the face, lips, tongue and/or larynx has been reported, in some cases after the first dose.
 - December 2011- Adverse reaction of pruritis and urticaria added.

Conclusion and Recommendations

The College of Pharmacy does not recommend any changes to this category at this time.

Utilization Details of Bladder Control Medications: Calendar Year 2011

MEDICATION	CLAIMS	UNITS	DAYS	MEMBERS	COST	UNITS/ DAY	CLAIMS/ MEMBER	COST/ DAY	PERCENT COST
OXYBUTYNIN TAB 5MG	5,616	380,937	171,424	1,672	\$55,323.26	2.22	3.36	\$0.32	5.93%
DETROL TAB 2MG	1,621	95,790	50,372	482	\$275,985.31	1.9	3.36	\$5.48	29.58%
DETROL LA CAP 4MG	1,094	44,111	42,016	172	\$216,700.40	1.05	6.36	\$5.16	23.22%
OXYBUTYNIN SYP 5MG/5ML	1,072	275,416	29,221	324	\$11,670.37	9.43	3.31	\$0.40	1.25%
SANCTURA XR CAP 60MG	427	15,745	14,022	108	\$76,101.67	1.12	3.95	\$5.43	8.16%
OXYBUTYNIN TAB 10MG ER	366	15,267	12,012	51	\$20,143.56	1.27	7.18	\$1.68	2.16%
VESICARE TAB 5MG	305	11,998	10,888	44	\$62,218.02	1.1	6.93	\$5.71	6.67%
ENABLEX TAB 15MG	238	9,367	8,452	42	\$44,871.50	1.11	5.67	\$5.31	4.81%
DETROL TAB 1MG	209	12,084	6,357	81	\$34,247.05	1.9	2.58	\$5.39	3.67%
OXYBUTYNIN TAB 15MG ER	192	9,533	6,898	36	\$15,548.61	1.38	5.33	\$2.25	1.67%
VESICARE TAB 10MG	187	6,130	6,070	34	\$32,288.22	1.01	5.5	\$5.32	3.46%
TOVIAZ TAB 8MG	142	4,260	4,260	20	\$19,468.72	1	7.1	\$4.57	2.09%
ENABLEX TAB 7.5MG	124	4,922	4,202	26	\$23,675.04	1.17	4.77	\$5.63	2.54%
DETROL LA CAP 2MG	119	4,468	4,438	14	\$22,178.97	1.01	8.5	\$5.00	2.38%
FLAVOXATE TAB 100MG	105	5,602	1,885	69	\$5,152.48	2.97	1.52	\$2.73	0.55%
OXYBUTYNIN TAB 5MG ER	91	3,878	3,509	21	\$5,681.73	1.11	4.33	\$1.62	0.61%
TOVIAZ TAB 4MG	39	1,170	1,170	10	\$5,309.16	1	3.9	\$4.54	0.57%
TROSPIMUM CL TAB 20MG	23	1,360	680	7	\$3,077.46	2	3.29	\$4.53	0.33%
OXYTROL DIS 3.9MG/24	13	136	454	2	\$3,342.43	0.3	6.5	\$7.36	0.36%
SANCTURA TAB 20MG	1	60	30	1	\$142.72	2	1	\$4.76	0.02%
TOTALS:	11,984	902,234	378,360	2,936*	\$933,126.68	2.38	4.08	\$2.47	100.00%

*Total number of unduplicated members